- Home
- VRDN vs ADUS Comparison
VRDN vs ADUS Comparison
Compare VRDN & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | ADUS |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VRDN | ADUS |
|---|---|---|
| Price | $23.03 | $114.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $35.46 | ★ $133.78 |
| AVG Volume (30 Days) | ★ 1.6M | 176.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.40 |
| EPS | N/A | ★ 2.85 |
| Revenue | ★ $5,706,000.00 | N/A |
| Revenue This Year | $13.73 | $9.17 |
| Revenue Next Year | $279.00 | $4.70 |
| P/E Ratio | ★ N/A | $40.24 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.18 | $87.95 |
| 52 Week High | $34.29 | $124.44 |
Technical Indicators
Market Signals| Indicator | VRDN | ADUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.42 | 46.39 |
| Support Level | $21.62 | $114.12 |
| Resistance Level | $24.86 | $117.46 |
| Average True Range (ATR) | 0.77 | 2.67 |
| MACD | -0.23 | -0.98 |
| Stochastic Oscillator | 43.52 | 10.15 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.